



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA)
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24
E-mail: admin@jagsonpal.com

Audited Financial Results for the Quarter/year ended 31.03.2009

Particulars	(Rs. in lacs)			
	Quarter ended 31.03.2009 Audited	Quarter ended 31.03.2008 Audited	12 Months ended 31.03.2009 Audited	12 Months ended 31.03.2008 Audited
1 Net sales/Income from Operations	3235.16	3315.79	13619.76	15009.39
2 Other income	27.06	25.50	27.06	25.50
3 Total Income (1+2)	3262.22	3341.29	13646.82	15034.89
4 Expenditure				
a. (Inc.)/Dec. in Stock in trade and work in progress	-401.28	-223.34	787.24	1003.64
b. Consumption of Raw Materials	2086.41	2095.58	6338.40	5486.71
c. Purchase of traded goods	133.91	125.43	764.68	2640.23
d. Employees Cost	485.53	514.24	1969.07	2018.12
e. Depreciation	27.49	48.07	124.98	168.72
f. Other Expenditure	529.32	525.05	2214.67	2563.15
g. Total	2861.38	3085.03	12199.04	13880.57
5 Interest	114.06	161.44	457.93	635.14
6 Exceptional Items				
7 Profit(+)/Loss(-) from Ordinary Activities before tax (3) - (4+5+6)	286.78	94.82	989.85	519.18
8 Tax expense	175.62	54.36	372.62	211.58
9 Net Profit(+)/Loss(-) from Ordinary Activities after tax (7-8)	111.16	40.46	617.23	307.60
10 Extraordinary Items (net of tax expense)				
11 Net Profit (+) Loss (-) for the period (9-10)	111.16	40.46	617.23	307.60
12 Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90
13 Reserves excluding Revaluation reserves as per Balance sheet of pr. accounting yr.			5277.85	4737.24
14 Earnings Per Share (EPS)				
a. Basic & diluted EPS before extraordinary items for the period.	0.42	0.15	2.36	1.17
b. Basic & diluted EPS after extraordinary items for the period.	0.42	0.15	2.36	1.17
15 Public shareholding :				
- Number of shares	8962320	8962320	8962320	8962320
- Percentage of Shareholding	34.21%	34.21%	34.21%	34.21%

Notes

- The Financial Results for the Quarter ended 31.03.2009 have been reviewed by the Auditors as well as Audit Committee. The Board of Directors has taken on record the financial Results at its meeting held on 30.06.2009
- The Board has recommended a dividend of Rs.0.25 only on 2,61,98,000 Equity Shares of Rs. 5/- each for the Financial Year ended 31.03.2009
- No complaints were pending at the beginning/end of the quarter ended 31.03.2009. However 29 requests for change of address/dividend revalidation/Annual Reports etc. were received & promptly responded to during the quarter.
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.
- The new manufacturing facility at Pantnagar, Uttarakhand, set up with a cost of Rs. 2462 lacs, started production in April, 2009.

Place : New Delhi
Date : 30.06.2009



By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
Managing Director